| Novartis: Study shows benefits of Xolair | Posted on 06/10/2008 in Pharmaceutical Company Product News Novartis has announced new study results showing the potential benefits of Xolair in children with moderate-to-severe allergic asthma.
The company said the data shows the compound to significantly reduce asthma attacks in children aged six to 11 years old.
It added Xolair could provide a novel approach to the treatment of asthma in children by targeting the root cause of symptoms in these patients - immunoglobulin E (IgE).
The firm noted asthma is the most common chronic disease of childhood, with the condition affecting around 20 per cent of children in some countries, with 78 per cent of these cases associated with high levels of IgE.
Professor Bobby Lanier of the University of North Texas Health Science Centre, said: "These data represent an important new approach to treating allergic asthma in children who remain uncontrolled despite their treatment."
He added these children are especially vulnerable, with some experiencing diminished quality of lives or even reduced life expectancy as a result of this disease.
In January 2008, Novartis said the launch of Xolair had supported its positive results, with the company recording record net sales of $39.8 billion (20 billion pounds) during 2007, a rise of eight per cent on the previous year.Other news stories from 06/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
